SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Pre-Tax Margin

Income before tax as a percentage of revenue.

SIGA Technologies, Inc.NASDAQ: SIGA

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -64.8%

Pre-tax margin was -64.8% in Q1 FY2026, down 56.7 pp from a year earlier. On a trailing-twelve-month basis it was 28.7%, down 23.0 pp year over year. Over 3 fiscal years it narrowed by 7.7 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-64.8%+144.3 pp QoQ
Last fiscal yearDec 2025
32.1%-22.7 pp YoY
LTMMar 2026
28.7%-23.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-56.7 pp——
1 year-22.7 pp——
3 years-7.7 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
32.1%
Year-over-year change
-22.7pp

Pre-Tax Margin vs competitors

How SIGA compares with its peers on the latest reported figures

  • SIGA's LTM Mar 2026 pre-tax margin of 28.7% is the 3rd highest of the 9 companies compared; the peer median is -0.4%.
  • Its year-over-year change of -23.0 pp is the 7th highest of 9, against a peer median of +8.9 pp.
  • Over three fiscal years its change of -7.7 pp compares with a peer median of +45.2 pp.
SIGA Competitors Peer median
Pre-Tax Margin for SIGA and competitors
Company Period LTM level YoY 3-year change
DRIODarioHealth Corp.LTM Mar 2026296.1% +455.3 pp+38.8 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202640.7% +21.9 pp+90.1 pp
SIGASIGA Technologies, Inc.LTM Mar 202628.7% -23.0 pp-7.7 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 20260.8% +6.1 pp+3.8 pp
EBSEmergent BioSolutions Inc.LTM Mar 20260.5% +7.0 pp+30.7 pp
SNDLSNDL Inc.LTM Mar 2026-1.3% +10.8 pp+51.7 pp
ESPREsperion Therapeutics, Inc.LTM Mar 2026-1.3% +57.7 pp+304.4 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-137.1% -37.0 pp-74.0 pp
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-165.7% -194.1 pp+164.3 pp
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding SIGA) -0.4%+8.9 pp+45.2 pp

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue133.67M110.78M139.92M138.72M94.6M
Cost of Revenue16.6M10.43M17.83M31.29M29.7M
Gross Profit117.07M100.34M122.09M107.43M64.87M
Gross Margin87.6%90.6%87.3%77.4%68.6%
Research & Development9.94M22.53M16.43M12.31M6.53M
Selling, General & Admin18.03M35.12M22.04M25.14M3.13M
Operating Expenses27.98M57.64M38.47M37.45M41.17M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
EBITDA89.83M44.65M88.31M76.61M30.96M
EBITDA Margin67.2%40.3%63.1%55.2%32.7%
Operating Income89.09M42.7M83.62M69.98M23.7M
Operating Margin66.7%38.5%59.8%50.4%25.1%
Interest Income00006.68M
Interest Expense00000
Other Income / Expenses218.94K1.43M4.16M6.09M6.7M
Income Before Tax89.31M44.13M87.78M76.07M30.4M
Pre-Tax Margin66.8%39.8%62.7%54.8%32.1%
Income Tax Expense19.86M10.23M19.71M16.86M7.1M
Net Income69.45M33.9M68.07M59.21M23.3M
Net Margin52.0%30.6%48.6%42.7%24.6%
EPS (Basic)0.920.460.950.830.33
EPS (Diluted)0.910.460.950.830.33
Weighted Avg Shares75.32M72.93M71.36M71.25M71.6M
Weighted Avg Shares (Diluted)76.4M73.55M71.68M71.77M71.6M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.